ghk-cu clinical studies dosage trial injection GHK-Cu and Protocol: A Medical Provider's Guide to the ghk-cu clinical trials Peptide Dosage

8 ) and exhibited less nerve damage in various brain areas ( Table 8, Fig

Despite a relatively short half-life of approximately 30 minutes, the peptide triggers gene expression changes that persist and cascade independently of its continued presence

doi:10.1371/journal.pone.0033944 Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, Hillegass WB, Rocha-Singh K, Moon TE, Whitehouse MJ et al (2002) Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial

Safety, and the gray market Short-term, the small human studies that exist havent flagged anything serious